NCT07485400Not yet recruiting
Aerobic Interval vs Continuous Training on Heart Rate-Power Decoupling in Ischemic Heart Disease
Effects of Long Extensive Aerobic Interval Training Versus Long Extensive Continuous Training on Heart Rate-Power Decoupling in Patients With Ischemic Heart Disease: A Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
This study is a randomized, parallel-group clinical trial with assessor and statistical analyst blinding, conducted at a single center. Participants with stable ischemic heart disease enrolled in a cardiac rehabilitation program will be randomly allocated to one of two aerobic exercise interventions: long extensive continuous aerobic training (zone 2) or long extensive aerobic interval training (zone 3). Both groups will participate in supervised exercise sessions twice weekly for a period of 8 weeks, integrated into the standard cardiac rehabilitation program. Assessments will be performed at baseline, immediately after the intervention period (8 weeks), and after a 4-week follow-up period without supervised training to evaluate potential detraining effects. The primary outcome is heart rate-power decoupling during a prolonged submaximal cycling exercise test, used as an indicator of cardiovascular efficiency. Secondary outcomes include heart rate response during submaximal exercise, exercise tolerance, heart rate recovery, blood pressure, functional capacity, quality of life, and adherence to the training program. The objective of this study is to compare the effects of long extensive aerobic interval training versus long extensive continuous training on heart rate-power decoupling and related cardiovascular and functional outcomes in patients with ischemic heart disease undergoing cardiac rehabilitation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 16 Mar 2026
- Start date
- 17 Mar 2026
- Primary completion date
- 17 May 2026
- Lead sponsor
- Universidad Complutense de Madrid
- Diseases
- Coronary artery disease
- NCT number
- NCT07485400
What you commit to
- Study type: Interventional
- Planned participants: 48
- From 17 Mar 2026 to the primary completion date, 17 May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant diseases that may limit participation or compromise safety (e.g., advanced pulmonary disease, severe renal failure, severe neuromuscular disorders).
- Participation in another clinical trial or concurrent rehabilitation program.
Other illness
- High prognostic risk, defined by:
- Killip class \> III (moderate to severe heart failure).
- Recent acute myocardial infarction (\< 1 month) with clinical instability.
- Active anginal symptoms or decompensated heart failure.
- Physical capacity \< 5 METs on functional testing, indicating severely reduced exercise capacity.
- Presence of complex or unstable arrhythmias contraindicating vigorous physical exercise.
- Absolute medical contraindications to maximal strength or interval training (e.g., aortic aneurysm, uncontrolled hypertension).
Other
- Inability to comply with attendance requirements or to follow the intervention protocol.
Who the study is looking for
- Confirmed diagnosis of cardiovascular disease requiring cardiac rehabilitation, with medical indication for a supervised exercise training program.
- Prognostic risk classified as low or moderate according to the clinical risk stratification established in the unit, considering:
- Killip class I or II (absence or mild heart failure)¹.
- Absence of recent acute myocardial infarction (\< 1 month) or presence of a stable previous infarction.
- Stable and well-controlled cardiovascular symptoms.
- Physical capacity demonstrated in functional tests ≥ 5 METs, preferably \> 7 METs for low-risk patients.
- Age between 40 and 75 years.
- Ability to perform physical exercise without absolute contraindications.
- Written informed consent and willingness to attend the scheduled sessions twice per week for 8 weeks.
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.